Financial Performance Forecast - The company expects a net profit of between 25 million and 32 million yuan for the first half of 2024, representing a year-on-year growth of 37.46% to 75.95% compared to 18.1867 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between 25 million and 32 million yuan, indicating a growth of 52.94% to 95.76% from 16.3467 million yuan year-on-year[2]. - The company emphasizes that the performance forecast data is preliminary and has not been audited by registered accountants[3][6]. - The specific financial data for the first half of 2024 will be detailed in the company's half-year report[6]. Revenue Growth - The pharmaceutical industrial segment's revenue has been continuously increasing due to the gradual expansion of national sales channels[4]. - The retail pharmacy business has seen growth in revenue and gross margin, attributed to an increase in the number of retail pharmacy stores and the completion of acquisitions included in the consolidated financial statements[5]. Investment Advisory - The company advises investors to make cautious decisions and be aware of investment risks[6].
达嘉维康(301126) - 2024 Q2 - 季度业绩预告